- The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer. Breast Care. 2010 Information Resource GET IT
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Times cited: 897